733 related articles for article (PubMed ID: 19555671)
1. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
[TBL] [Abstract][Full Text] [Related]
2. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease.
Sun Y; Wu XX; Yin Y; Gong FY; Shen Y; Cai TT; Zhou XB; Wu XF; Xu Q
Biochem Pharmacol; 2010 Jan; 79(2):229-38. PubMed ID: 19698701
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
4. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
5. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
6. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
7. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Gastroenterology; 2009 Mar; 136(3):978-89. PubMed ID: 19135996
[TBL] [Abstract][Full Text] [Related]
8. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
10. Involvement of innate immunity in the development of inflammatory and autoimmune diseases.
Tlaskalová-Hogenová H; Tucková L; Stepánková R; Hudcovic T; Palová-Jelínková L; Kozáková H; Rossmann P; Sanchez D; Cinová J; Hrncír T; Kverka M; Frolová L; Uhlig H; Powrie F; Bland P
Ann N Y Acad Sci; 2005 Jun; 1051():787-98. PubMed ID: 16127016
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
12. A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
Vergnolle N; Cellars L; Mencarelli A; Rizzo G; Swaminathan S; Beck P; Steinhoff M; Andrade-Gordon P; Bunnett NW; Hollenberg MD; Wallace JL; Cirino G; Fiorucci S
J Clin Invest; 2004 Nov; 114(10):1444-56. PubMed ID: 15545995
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic action of ghrelin in a mouse model of colitis.
Gonzalez-Rey E; Chorny A; Delgado M
Gastroenterology; 2006 May; 130(6):1707-20. PubMed ID: 16697735
[TBL] [Abstract][Full Text] [Related]
15. Ameliorating effect of saporin-conjugated anti-CD11b monoclonal antibody in a murine T-cell-mediated chronic colitis.
Kanai T; Uraushihara K; Totsuka T; Nemoto Y; Fujii R; Kawamura T; Makita S; Sawada D; Yagita H; Okumura K; Watanabe M
J Gastroenterol Hepatol; 2006 Jul; 21(7):1136-42. PubMed ID: 16824065
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model.
Pender SL; Chance V; Whiting CV; Buckley M; Edwards M; Pettipher R; MacDonald TT
Gut; 2005 Aug; 54(8):1114-20. PubMed ID: 16009684
[TBL] [Abstract][Full Text] [Related]
17. Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease.
Powrie F; Uhlig H
Novartis Found Symp; 2004; 263():164-74; discussion 174-8, 211-8. PubMed ID: 15669641
[TBL] [Abstract][Full Text] [Related]
18. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
19. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
20. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
